Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | REN | P00797 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7809493 | 1.00 | GAA (0.39) | GAAEPHX1TDP1EPHX2NFKB1 | |
| SCHEMBL29560346 | 1.00 | GAA (0.39) | GAAEPHX1TDP1EPHX2NFKB1 | |
| SCHEMBL19098270 | 1.00 | GAA (0.39) | GAAEPHX1TDP1EPHX2NFKB1 | |
| SCHEMBL19098269 | 1.00 | GAA (0.39) | GAAEPHX1TDP1EPHX2NFKB1 | |
| SCHEMBL8564507 | 0.88 | GAA (0.39) | GAAEPHX1TDP1EPHX2NFKB1 | |
| SCHEMBL8559748 | 0.88 | GAA (0.39) | GAAEPHX1TDP1EPHX2NFKB1 | |
| SCHEMBL8559743 | 0.88 | GAA (0.39) | GAAEPHX1TDP1EPHX2NFKB1 | |
| SCHEMBL8559648 | 0.88 | GAA (0.39) | GAAEPHX1TDP1EPHX2NFKB1 | |
| SCHEMBL2184286 | 0.88 | GAA (0.39) | GAAEPHX1TDP1EPHX2NFKB1 | |
| SCHEMBL2182196 | 0.88 | GAA (0.39) | GAAEPHX1TDP1EPHX2NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562909-B2 | Fused quadracyclic compounds, compositions and uses thereof | Tabomedex Biosciences, LLC (US) | 2020-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562909-B2 | Fused quadracyclic compounds, compositions and uses thereof | MKNK2, CYP2J2, PTGS2 | GAA 2044/4885EPHX1 2703/4885TDP1 4112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.